PortalPublikationenIntegrated safety profile of selinexor in multiple myeloma: ...

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

Standard

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. / Gavriatopoulou, Maria; Chari, Ajai; Chen, Christine; Bahlis, Nizar; Vogl, Dan T; Jakubowiak, Andrzej; Dingli, David; Cornell, Robert F; Hofmeister, Craig C; Siegel, David; Berdeja, Jesus G; Reece, Donna; White, Darrell; Lentzsch, Suzanne; Gasparetto, Cristina; Huff, Carol Ann; Jagannath, Sundar; Baz, Rachid; Nooka, Ajay K; Richter, Joshua; Abonour, Rafat; Parker, Terri L; Yee, Andrew J; Moreau, Philippe; Lonial, Sagar; Tuchman, Sascha; Weisel, Katja C; Mohty, Mohamad; Choquet, Sylvain; Unger, T J; Li, Kai; Chai, Yi; Li, Lingling; Shah, Jatin; Shacham, Sharon; Kauffman, Michael G; Dimopoulos, Meletios Athanasios.

in: LEUKEMIA, Jahrgang 34, Nr. 9, 09.2020, S. 2430-2440.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gavriatopoulou, M, Chari, A, Chen, C, Bahlis, N, Vogl, DT, Jakubowiak, A, Dingli, D, Cornell, RF, Hofmeister, CC, Siegel, D, Berdeja, JG, Reece, D, White, D, Lentzsch, S, Gasparetto, C, Huff, CA, Jagannath, S, Baz, R, Nooka, AK, Richter, J, Abonour, R, Parker, TL, Yee, AJ, Moreau, P, Lonial, S, Tuchman, S, Weisel, KC, Mohty, M, Choquet, S, Unger, TJ, Li, K, Chai, Y, Li, L, Shah, J, Shacham, S, Kauffman, MG & Dimopoulos, MA 2020, 'Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials', LEUKEMIA, Jg. 34, Nr. 9, S. 2430-2440. https://doi.org/10.1038/s41375-020-0756-6

APA

Gavriatopoulou, M., Chari, A., Chen, C., Bahlis, N., Vogl, D. T., Jakubowiak, A., Dingli, D., Cornell, R. F., Hofmeister, C. C., Siegel, D., Berdeja, J. G., Reece, D., White, D., Lentzsch, S., Gasparetto, C., Huff, C. A., Jagannath, S., Baz, R., Nooka, A. K., ... Dimopoulos, M. A. (2020). Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. LEUKEMIA, 34(9), 2430-2440. https://doi.org/10.1038/s41375-020-0756-6

Vancouver

Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. LEUKEMIA. 2020 Sep;34(9):2430-2440. https://doi.org/10.1038/s41375-020-0756-6

Bibtex

@article{c521b5b72e164784960d47d9648c4c70,
title = "Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials",
abstract = "Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures. Selinexor reduced both platelets and neutrophils over the first cycle of treatment and reached a nadir between 28 and 42 days. Platelet transfusions and thrombopoietin receptor agonists were effective at treating thrombocytopenia, and granulocyte colony stimulating factors were effective at resolving neutropenia. The onset of gastrointestinal side effects (nausea, vomiting, and diarrhea) was most common during the first 1-2 weeks of treatment. Nausea could be mitigated with 5-HT3 antagonists and either neurokinin 1 receptor antagonists, olanzapine, or cannbainoids. Loperamide and bismuth subsalicylate ameliorated diarrhea. The primary constitutional side effects of fatigue and decreased appetite could be managed with methylphenidate, megestrol, cannabinoids or olanzapine, respectively. Hyponatremia was highly responsive to sodium replacement. Selinexor has well-established adverse effects that mainly occur within the first 8 weeks of treatment, are reversible, and respond to supportive care.",
author = "Maria Gavriatopoulou and Ajai Chari and Christine Chen and Nizar Bahlis and Vogl, {Dan T} and Andrzej Jakubowiak and David Dingli and Cornell, {Robert F} and Hofmeister, {Craig C} and David Siegel and Berdeja, {Jesus G} and Donna Reece and Darrell White and Suzanne Lentzsch and Cristina Gasparetto and Huff, {Carol Ann} and Sundar Jagannath and Rachid Baz and Nooka, {Ajay K} and Joshua Richter and Rafat Abonour and Parker, {Terri L} and Yee, {Andrew J} and Philippe Moreau and Sagar Lonial and Sascha Tuchman and Weisel, {Katja C} and Mohamad Mohty and Sylvain Choquet and Unger, {T J} and Kai Li and Yi Chai and Lingling Li and Jatin Shah and Sharon Shacham and Kauffman, {Michael G} and Dimopoulos, {Meletios Athanasios}",
year = "2020",
month = sep,
doi = "10.1038/s41375-020-0756-6",
language = "English",
volume = "34",
pages = "2430--2440",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "9",

}

RIS

TY - JOUR

T1 - Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

AU - Gavriatopoulou, Maria

AU - Chari, Ajai

AU - Chen, Christine

AU - Bahlis, Nizar

AU - Vogl, Dan T

AU - Jakubowiak, Andrzej

AU - Dingli, David

AU - Cornell, Robert F

AU - Hofmeister, Craig C

AU - Siegel, David

AU - Berdeja, Jesus G

AU - Reece, Donna

AU - White, Darrell

AU - Lentzsch, Suzanne

AU - Gasparetto, Cristina

AU - Huff, Carol Ann

AU - Jagannath, Sundar

AU - Baz, Rachid

AU - Nooka, Ajay K

AU - Richter, Joshua

AU - Abonour, Rafat

AU - Parker, Terri L

AU - Yee, Andrew J

AU - Moreau, Philippe

AU - Lonial, Sagar

AU - Tuchman, Sascha

AU - Weisel, Katja C

AU - Mohty, Mohamad

AU - Choquet, Sylvain

AU - Unger, T J

AU - Li, Kai

AU - Chai, Yi

AU - Li, Lingling

AU - Shah, Jatin

AU - Shacham, Sharon

AU - Kauffman, Michael G

AU - Dimopoulos, Meletios Athanasios

PY - 2020/9

Y1 - 2020/9

N2 - Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures. Selinexor reduced both platelets and neutrophils over the first cycle of treatment and reached a nadir between 28 and 42 days. Platelet transfusions and thrombopoietin receptor agonists were effective at treating thrombocytopenia, and granulocyte colony stimulating factors were effective at resolving neutropenia. The onset of gastrointestinal side effects (nausea, vomiting, and diarrhea) was most common during the first 1-2 weeks of treatment. Nausea could be mitigated with 5-HT3 antagonists and either neurokinin 1 receptor antagonists, olanzapine, or cannbainoids. Loperamide and bismuth subsalicylate ameliorated diarrhea. The primary constitutional side effects of fatigue and decreased appetite could be managed with methylphenidate, megestrol, cannabinoids or olanzapine, respectively. Hyponatremia was highly responsive to sodium replacement. Selinexor has well-established adverse effects that mainly occur within the first 8 weeks of treatment, are reversible, and respond to supportive care.

AB - Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures. Selinexor reduced both platelets and neutrophils over the first cycle of treatment and reached a nadir between 28 and 42 days. Platelet transfusions and thrombopoietin receptor agonists were effective at treating thrombocytopenia, and granulocyte colony stimulating factors were effective at resolving neutropenia. The onset of gastrointestinal side effects (nausea, vomiting, and diarrhea) was most common during the first 1-2 weeks of treatment. Nausea could be mitigated with 5-HT3 antagonists and either neurokinin 1 receptor antagonists, olanzapine, or cannbainoids. Loperamide and bismuth subsalicylate ameliorated diarrhea. The primary constitutional side effects of fatigue and decreased appetite could be managed with methylphenidate, megestrol, cannabinoids or olanzapine, respectively. Hyponatremia was highly responsive to sodium replacement. Selinexor has well-established adverse effects that mainly occur within the first 8 weeks of treatment, are reversible, and respond to supportive care.

U2 - 10.1038/s41375-020-0756-6

DO - 10.1038/s41375-020-0756-6

M3 - SCORING: Journal article

C2 - 32094461

VL - 34

SP - 2430

EP - 2440

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 9

ER -